The pandemic provided a reason to the stock market to be excited about the pharma sector that had been facing lacklustre prospects amid challenges in the US business, USFDA compliance issues, pricing pressure, big-bang acquisitions not working out on expected lines and modest growth in the domestic market.
Negative Breakout: These 7 stocks cross below their 200 DMAs
200 DMA: Rs 1429.84| LTP: Rs 1406.3